Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 2/2012

01-04-2012 | Adis Profile Report

DTaP5-IPV-Hib Vaccine (Pediacel®)

Profile Report

Author: James E. Frampton

Published in: BioDrugs | Issue 2/2012

Login to get access

Excerpt

Practically all EU countries recommend vaccination of infants against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib). However, differences in vaccination schedules exist. For example, some countries recommend a two-dose primary series administered at 3 and 5 months of age (e.g. Italy, Norway, Finland, and Sweden), whereas others recommend a three-dose series administered at 2, 3, and 4 months of age (e.g. UK, France, and Germany) or 2, 4, and 6 months of age (e.g. Spain and Portugal).[1,2] In addition, most, but not all, countries recommend a booster at ≈11–18 months of age.[1,2] …
Literature
1.
Esposito S, Principi N. Differences in vaccinations in European Union. Hum Vaccin 2008; 4 (4): 313–5PubMedCrossRef
2.
3.
Dhillon S, Keam SJ. DTaP-IPV/Hib vaccine (Pentacel®). Pediatr Drugs 2008; 10 (6): 405–16CrossRef
4.
Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™): a review of its use as primary and booster vaccination. Drugs 2010 May 28; 70 (8): 1021–58PubMedCrossRef
5.
6.
Infanrix-IPV (diphtheria, tetanus, pertussis [acellular component] and poliomyelitis [inactivated] vaccine [adsorbed]): summary of product characteristics. Uxbridge: GlaxoSmithKline, 2010
7.
Actacel™: concise prescribing information. Singapore: Zuellig Pharma, 2011
8.
Pediacel (diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine [adsorbed]): summary of product characteristics. Maidenhead: Sanofi Pasteur MSD Ltd, 2010
9.
Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate [tetanus toxoid conjugate]) vaccine: suspension for intramuscular injection (US prescribing information). Swiftwater (PA): Sanofi Pasteur Inc., 2009
10.
Pediarix (diphtheria and tetanus toxoids and acellular pertussis adsorbed, Hepatitis B [recombinant] and inactivated poliovirus vaccine): suspension for intramuscular injection (US prescribing information). Research Triangle Park (NC): GlaxoSmithKline Inc., 2010
11.
Infanrix-IPV+Hib (diphtheria, tetanus, pertussis [acellular component], poliomyelitis [inactivated] and Haemophilus type b conjugate vaccine [adsorbed]): summary of product characteristics. Uxbridge: GlaxoSmithKline, 2009
12.
Capeding MR, Cadorna-Carlos J, Book-Montellano M, et al. Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull WHO 2008; 86 (6): 443–51PubMed
13.
Pentavac® (diphtheria, tetanus, pertussis [acellular, component], poliomyelitis [inactivated] and Haemophilus influenzae type b conjugate vaccine [adsorbed]): summary of product characteristics. Brussels: Sanofi Pasteur MSD, 2010
14.
15.
Grimprel E, Wysocki J, Boisnard F, et al. Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, and 4, and 12 to 18 months of age: a phase III, single-blind, randomized, controlled, multicentre study. Vaccine 2011; 29 (43): 7370–8PubMedCrossRef
16.
Lin TY, Wang YH, Chang LY, et al. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Int J Infect Dis 2007 Mar; 11 (2): 129–36PubMedCrossRef
17.
Wiedenmayer KA, Weiss S, Chattopadhyay C, et al. Simplifying paediatric immunization with a fully liquid DTP-HepB-Hib combination vaccine: evidence from a comparative time-motion study in India. Vaccine 2009; 27: 655–9PubMedCrossRef
18.
Andrews N, Stowe J, Wise L, et al. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine 2010 Oct 18; 28 (44): 7215–20PubMedCrossRef
19.
Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009 Feb; 16 (2): 194–9PubMedCrossRef
20.
Moss SJ, Fenton AC, Toomey J, et al. Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age. Clin Vaccine Immunol 2010 Mar; 17 (3): 311–6PubMedCrossRef
21.
22.
Vesikari T, Silfverdal SA, Boisnard F, et al. Immunogenicity and safety of a fully liquid DTaP5-IPV-Hib versus DTaP3-IPV/Hib at 3, 5, and 12 months of age [abstract plus poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice
23.
Kitchin NR, Southern J, Morris R, et al. Evaluation of a diphtheria-tetanusacellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007 Jan; 92 (1): 11–6PubMedCrossRef
24.
Kitchin N, Southern J, Morris R, et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 2009 Aug 13; 27 (37): 5096–102PubMedCrossRef
25.
Gold R, Barreto L, Ferro S, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol 2007 Jul; 18 (4): 241–8PubMed
26.
Berner R, Boisnard F, Thomas S, et al. Safety and immunogenicity of fully liquid DTaP5-IPV-Hib versus DTaP3-HBV-IPV/Hib as a booster at 11–18 months of age coadministered with PCV7 [abstract plus poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice
27.
28.
Lin TY, Wang YH, Huang YC, et al. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Int J Infect Dis 2007 Nov; 11 (6): 488–95PubMedCrossRef
29.
Capeding MR, Unalivia L, Victorio MV, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine in infants at 6, 10, 14 weeks of age (EPI schedule) [poster]. 3rd World Congress of Pediatric Infectious Diseases (WSPID); 2002 Nov 19–23; Santiago
30.
Castaneda JL, Gonzalez N, Chavez R, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine with full primary IPV or sequential IPV-OPV in Mexican infants [poster]. 11th International Congress on Infectious Diseases (ICID); 2004 Mar 4–7; Cancun
31.
Klinger CL, Snape MD, John T, et al. Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine [abstract no. GI-2118]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, and 46th Annual Meeting of the Infectious Diseases Society of America — a joint meeting; 2008 Oct 25–28; Washington, DC
32.
Frampton JE. DTaP5-IPV-Hib Vaccine (Pediacel®). Pediatr Drugs 2011; 13 (6): 401–15CrossRef
Metadata
Title
DTaP5-IPV-Hib Vaccine (Pediacel®)
Profile Report
Author
James E. Frampton
Publication date
01-04-2012
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 2/2012
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/11608730-000000000-00000

Other articles of this Issue 2/2012

BioDrugs 2/2012 Go to the issue

Adis Drug Clinical Q&A

Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria

Current Opinion

Biologic Rheumatoid Arthritis Therapies

Open Access: Current Opinion

Clinical Relevance of Botulinum Toxin Immunogenicity

Review Article

Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

Systematic Review

Hyaluronic Acid for the Treatment of Osteoarthritis in all Joints Except the Knee

Review Article

Rituximab